Filing Flows › Comparisons › PRLD vs QURE
Prelude Therapeutics vs uniQure N.V.: PRLD and QURE compared
Prelude Therapeutics is the larger company: $5.7M of revenue in its latest quarter (Q2 2026) against $5.2M for uniQure N.V. (Q3 2026).
Where the money goes: PRLD and QURE
Prelude Therapeutics (PRLD) · Q2 2026
Prelude Therapeutics, Q2 2026: revenue $5.7M, operating margin -270.9%, net loss $13.9M, operating cash flow −$15.6M. The chart follows the revenue to costs, profit and cash.
uniQure N.V. (QURE) · Q3 2026
uniQure N.V., Q3 2026: revenue $5.2M (+40% year over year), net loss $61.2M, operating cash flow −$47.8M. The chart follows the revenue to costs, profit and cash.
| Prelude Therapeutics (PRLD) | uniQure N.V. (QURE) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q3 2026 |
| Revenue | $5.7M | $5.2M |
| Revenue growth, Y/Y | — | +40% |
| Operating margin | -270.9% | n/m |
| Net earnings | −$13.9M | −$61.2M |
| Net margin | -244.1% | — |
| Operating cash flow | −$15.6M | −$47.8M |
Questions
Which is bigger, Prelude Therapeutics or uniQure N.V.?
Prelude Therapeutics is the larger company: $5.7M of revenue in its latest quarter (Q2 2026) against $5.2M for uniQure N.V. (Q3 2026).
More: Prelude Therapeutics earnings · how Prelude Therapeutics makes money · uniQure N.V. earnings · how uniQure N.V. makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 11, 2026; 10-Q filed Nov 4, 2026). Fiscal quarters can end on different dates. Not investment advice.